
GC10314
Imatinib
Also listed as Imatinib (STI571)
Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity· Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively· Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV
ChemicalCAS152459-95-5MW493.6FormulaC29H31N7O
- CAS number
- 152459-95-5
- Molecular weight
- 493.6
- Formula
- C29H31N7O
- Solubility
- ≥ 24·68mg/mL in DMSO
- InChIKey
- KTUFNOKKBVMGRW-UHFFFAOYSA-N
- Catalogue number
- GC10314
- Brand
- GLPBIO
Computed properties PubChem CID 5291 · XLogP 3.5 · TPSA 86.3 Ų · H-bond donors 2
- XLogP
- 3.5
- TPSA
- 86.3 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Rotatable bonds
- 7
- Heavy atoms
- 37
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
Computed descriptors from PubChem (CID 5291), public domain. Identity cross-checked against the supplier's molecular formula and weight — verify before use.
Ordering in Israel
- Lead time
- Ships from the manufacturer to your lab in 8–14 business days; customs and cold chain handled by LABO Scientific.
- Pricing
- Quoted in ILS, excl. VAT. Add the item to your quote and we confirm the final price, usually the same business day.
- Documents
- Lot certificate of analysis and manufacturer SDS are emailed with your order confirmation.
- Who we serve
- Universities, hospitals and biotech companies across Israel. Research use only — not for diagnostic or therapeutic use.
- Questions
- WhatsApp · +972-55-990-7576 · orders@labo.co.il